Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.
Nissen M, Marshall H, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber W, Jansen KU, Emini EA, Anderson AS, Zito ET, Girgenti D. Nissen M, et al. Among authors: jansen ku. Vaccine. 2015 Apr 8;33(15):1846-54. doi: 10.1016/j.vaccine.2015.02.024. Epub 2015 Feb 21. Vaccine. 2015. PMID: 25707693 Free article. Clinical Trial.
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.
Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, Kiviat NB, Jansen KU, Barber H, Smith JF, Tadesse A, Giacoletti K, Smith PR, Suhr G, Johnson DA. Fife KH, et al. Among authors: jansen ku. Vaccine. 2004 Jul 29;22(21-22):2943-52. doi: 10.1016/j.vaccine.2003.11.058. Vaccine. 2004. PMID: 15246631 Clinical Trial.
A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model.
Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, Noble L, Brown MJ, Zorman JK, Wang XM, Pancari G, Fan H, Isett K, Burgess B, Bryan J, Brownlow M, George H, Meinz M, Liddell ME, Kelly R, Schultz L, Montgomery D, Onishi J, Losada M, Martin M, Ebert T, Tan CY, Schofield TL, Nagy E, Meineke A, Joyce JG, Kurtz MB, Caulfield MJ, Jansen KU, McClements W, Anderson AS. Kuklin NA, et al. Among authors: jansen ku. Infect Immun. 2006 Apr;74(4):2215-23. doi: 10.1128/IAI.74.4.2215-2223.2006. Infect Immun. 2006. PMID: 16552052 Free PMC article.
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Villa LL, et al. Among authors: jansen ku. Vaccine. 2006 Jul 7;24(27-28):5571-83. doi: 10.1016/j.vaccine.2006.04.068. Epub 2006 May 15. Vaccine. 2006. PMID: 16753240 Clinical Trial.
Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design.
Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, Nunez L, Hagen M, Matsuka YV, Mininni T, Zhu D, Pavliak V, Green BA, Jansen KU, Anderson AS. Nanra JS, et al. Among authors: jansen ku. Vaccine. 2009 May 26;27(25-26):3276-80. doi: 10.1016/j.vaccine.2009.01.062. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200819
Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.
McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, Mason K, Jiang HQ, Zhu D, Mininni TL, Zlotnick GW, Hoiseth SK, Jones TR, Pride MW, Jansen KU, Anderson AS. McNeil LK, et al. Among authors: jansen ku. Vaccine. 2009 May 26;27(25-26):3417-21. doi: 10.1016/j.vaccine.2009.01.075. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200847
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.
Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. Murphy E, et al. Among authors: jansen ku. J Infect Dis. 2009 Aug 1;200(3):379-89. doi: 10.1086/600141. J Infect Dis. 2009. PMID: 19534597
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, Jansen KU, Devlin C, Gruber WC, Emini EA, Scott DA; 006 study group. Kieninger DM, et al. Among authors: jansen ku. Vaccine. 2010 Jun 7;28(25):4192-203. doi: 10.1016/j.vaccine.2010.04.008. Epub 2010 Apr 22. Vaccine. 2010. PMID: 20417262 Clinical Trial.
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. Jiang HQ, et al. Among authors: jansen ku. Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7. Vaccine. 2010. PMID: 20619376
247 results